Lifeboat Foundation

Scientists have created thin, elastic bottlebrush polymer films that can function as artificial muscles at significantly lower voltages than currently available materials, potentially enabling their use in safer medical devices and artificial organs.

Whether wriggling your toes or lifting groceries, muscles in your body smoothly expand and contract. Some polymers can do the same thing — acting like artificial muscles — but only when stimulated by dangerously high voltages. Now, researchers in ACS Applied Materials & Interfaces report a series of thin, elastic films that respond to substantially lower electrical charges. The materials represent a step toward artificial muscles that could someday operate safely in medical devices.

Artificial muscles could become key components of movable soft robotic implants and functional artificial organs. Electroactive elastomers, such as bottlebrush polymers, are attractive materials for this purpose because they start soft but stiffen when stretched. And they can change shape when electrically charged. However, currently available bottlebrush polymer films only move at voltages over 4,000 V, which exceeds the 50 V maximum that the U.S. Occupational Safety & Health Administration states is safe. Reducing the thickness of these films to less than 100 µm could lower the required voltages, but this hasn’t been done successfully yet for bottlebrush polymers. So, Dorina Opris and colleagues wanted to find a simple way to produce thinner films.

Taken in pill form, the drug would eliminate cells in the human body that are responsible for advancing the ageing process – potentially doubling our lifespan. But is this desirable?

As data scientist Izzy Miller puts it, the group chat is “a hallowed thing” in today’s society. Whether located on iMessage, WhatsApp, or Discord, it’s the place where you and your best friends hang out, shoot the shit, and share updates about life, both trivial and momentous. In a world where we are increasingly bowling alone, we can, at least, complain to the group chat about how much bowling these days sucks ass.

“My group chat is a lifeline and a comfort and a point of connection,” Miller tells The Verge. “And I just thought it would be hilarious and sort of sinister to replace it.”

So he did.

Sue Vincent, 69, from Solihull, said the drug enabled her to see her five grandchildren born – and led to her being awarded an MBE A woman described as “living proof” of the success of a new drug treating inherited cancer is “delighted” it has been approved for wider NHS use.

Do you like our content? Please support PRO Robots on Patreon.
—
https://www.patreon.com/PRORobots.
—
Your contributions will help us to create better content and to improve our service for you and our PRO Robots community. Every dollar counts and will help us keep working for you.
Thank you for your support!

All about AI: https://youtu.be/Ic8yVrm58lI

Continue reading “GPT-5: A New Era of Artificial Intelligence or the Beginning of the End of Mankind? | Pro Robots” »

Pictured: Illustration of CRISPR-Cas9 editing DNA / iStock, Artur Plawgo

Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid-and late-stage trials. As these programs mature, 2023 could be a pivotal year for companies in the space. Here are some highlights to look forward to as the year progresses.

CRISPR Therapeutics/Vertex Pharmaceuticals.

This review discusses generalist medical artificial intelligence, identifying potential applications and setting out specific technical capabilities and training datasets necessary to enable them, as well as highlighting challenges to its implementation.

In the last decade, we have witnessed biology bring us some incredible products and technologies: from mushroom-based packaging to animal-free hotdogs and mRNA vaccines that helped curb a global pandemic. The power of synthetic biology to transform our world cannot be overstated: this industry is projected to contribute to as much as a third of the global economic output by 2030, or nearly $30 trillion, and could impact almost every area of our lives, from the food we eat to the medicine we put in our bodies.

The leaders of this unstoppable bio revolution – many of whom you can meet at the SynBioBeta conference in Oakland, CA, on May 23–25 – are bringing the future closer every day through their ambitious vision, long-range strategy, and proactive oversight. These ten powerful women are shaping our world as company leaders, biosecurity experts, policymakers, and philanthropists focused on charting a new course to a more sustainable, equitable, clean, and safe future.

As an early pioneer in the high-throughput synthesis and sequencing of DNA, Emily Leproust has dedicated her life to democratizing gene synthesis to catapult the growth of synthetic biology applications from medicine, food, agriculture, and industrial chemicals to DNA data storage. She was one of the co-founders of Twist Bioscience in 2013 and is still leading the expanding company as CEO. To say that Twist’s silicon platform was a game-changer for the industry is an understatement. And it is no surprise that Leproust was recently honored with the BIO Rosalind Franklin Award for her work in the biobased economy and biotech innovation.

The procedure is a long, long way from being applicable to humans, the researchers stress. But their findings, published today in Nature Cardiovascular Research, reshape our understanding of the regenerative capabilities of the heart – and possibly other organs – and how they might be enhanced through preventive medical intervention.

“It’s a proof of concept,” says Tzahor, “and it points to new avenues of research that examine giving heart treatment not only after the damage happens, but from a preventive position that increases the capacity for recovery from an injury before the damage even occurs.”